On November 18, 2024, VelaVigo Cayman Limited (VelaVigo), a biotech company focusing on discovery and development of multi-specific antibodies and antibody-drug conjugates (ADC), announced it has entered into an agreement with Avenzo Therapeutics, Inc. (Avenzo) granting Avenzo an exclusive option to an exclusive license to develop, manufacture and commercialize a potential first-in-class Nectin4/TROP2 bispecific ADC globally (excluding Greater China). VelaVigo will maintain rights for Greater Ch...

On January 7, 2024, Argo Biopharma announced two exclusive license and collaboration agreements with Novartis in a historic move in the RNAi therapy field. Argo is set to receive an upfront payment of USD $185 Million from Novartis, with the potential for significant option and milestone payments, as well as a share in commercial sales. The combined potential value of the two deals could reach an impressive USD $4.165 Billion. Under the first agreement, Argo grants Novartis exclusive global deve...

Suzhou Ribo Life Science Co., Ltd and Ribocure Pharmaceuticals AB (together referred to as s internationalization, we anticipate more positive developments within our investment portfolio.

We are pleased to announce that TIBS has been awarded the Most Innovative Biomed Venture Capital Fund 2023 – Asia under Private Equity and Venture Capital Awards listed by Wealth and Finance International. We are humbled by the award and will continue our mission to help passionate scientists and entrepreneurs transform ground-breaking scientific innovations into cures for unmet medical needs.Please refer to the following link for the award list :Wealth Finance International Reveals the 2023 Wi...

Recently, Shanghai Argo Biopharmaceutical Co., Ltd (Argo Biopharma) announced the completion of US$ 42 million in Series A+ financing. This round of financing is led by SDIC Investment, with participation from Huagai Capital, Yuanxi Haihe Fund, and TIBS. This round of financing will be used to further promote the global development of four clinical pipelines and multiple preclinical candidate drug molecules. (PCC) discovery, modification platform and extra-hepatic delivery technology platform up...

On 30th August 2023, Epigenic Therapeutics, a TIBS-invested company, announced that it has raised USD 32 million in Series A round of financing co-led by Qiming Venture Partners and OrbiMed, with participation from existing investor Morningside Venture Capital. This round of financing will support the preclinical development and early clinical validation of two leading programs, the discovery of future pipelines, the expansion of the leadership team, and continued investments in the companys cor...

On 28th August 2023, HiFiBiO Therapeutics, a TIBS-invested company, was named as one of 2023’s “Fierce 15” biotechnology companies by Fierce Biotech. This annual special report features the most innovative and promising early-stage biotechnology companies in the industry. In curating this list, Fierce Biotech has considered a diverse range of factors, including the robustness of the companies’ technology, partnerships, venture support and competitive positioning within the market. The Fierce 15 ...

On 23 August 2023, Dizal Pharmaceutical Co., Ltd (SHA: 688192), a TIBS-invested company, announced that Sunvozertinib has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations, whose disease has progressed on or after platinum-based chemotherapy. Sunvozertinib, with its superior eff...

Cholesgen (Shanghai) Co.Ltd. (‘Cholesgen’) today announced an exciting newcollaboration with AstraZeneca to advance research and development in diseases relatedto high cholesterol. This three-year partnership will focus on validating genetic drug targetsand developing new therapies for clinical trials. Cholesgens early-stage portfolio willprovide several potential targets for the joint research effort, which will leverage thestrengths of both companies. As part of the agreement, Cholesgen will r...

Cholesgen (Shanghai) Co. Ltd., an incubated company of TIF Fund, has recently announced the completion of its Series A financing, raising more than RMB 100M (equivalent to USD 14.1M). The fundraising round was led by Gaorong Capital and syndicated by AZ-CICC Medical Fund, Wider Link Enterprise Investment Limited, Huangpu Biomedical Fund and TIF Fund.Despite the headwinds in the capital market, Cholesgens research and development to reach the next milestones as soon as possible.